File Download
 
 
Supplementary

Conference Paper: Prediction of post-hepatectomy HCC recurrence by circulating cancer stem cells
  • Basic View
  • Metadata View
  • XML View
TitlePrediction of post-hepatectomy HCC recurrence by circulating cancer stem cells
 
AuthorsFan, ST
Yang, ZF
Ho, DWY
Yu, WC
Wong, J
 
Issue Date2011
 
CitationThe 131st Annual Meeting of the American Surgical Association, Boca Raton, FL., 14-16 April 2011. [How to Cite?]
 
AbstractOBJECTIVE(S): Recurrence of HCC frequently occurs within the first year after hepatectomy probably due to circulating cancer cells that shed from the primary tumor prior to hepatectomy. Since cancer stem cells (CSCs) are more likely to initiate tumor growth than mature cancer cells, a high level of circulating CSCs may be a hint for HCC recurrence. This study aims to investigate whether circulating CSCs can predict recurrence of HCC after hepatectomy. METHODS: Multi-color flow cytometry was used to detect the number of circulating CSCs (CD45-CD90+CD44+) in the peripheral circulation of 82 patients of HCC one day before hepatectomy. The patients were monitored by CT or MRI for recurrence every three months. RESULTS: Forty-one (50%) patients had recurrence after a median follow-up period of 17.5 months (range 2.7–64.9 months). The patients with recurrence had a higher median level of circulating CSCs than those without recurrence (0.02% vs. 0.01%, p < 0.0001). Circulating CSCs >/=0.01% predicted intrahepatic recurrences (relative risk 3.54, 95% C.I. 1.41–8.88) and extrahepatic recurrences (relative risk 10.15, 95% C.I. 3–34.4). Patients with >0.01% circulating CSCs had a lower two-year disease-free rate (22.7% vs. 64.2%, p < 0.0001) and overall survival rate (58.5% vs. 94.1%, p = 0.0005) than those with </=0.01% circulating CSCs. On multivariate analysis, circulating CSCs >0.01%, tumor stage and tumor size were independent factors affecting the disease-free survival. CONCLUSIONS: Circulating CSCs predicted post-hepatectomy recurrence of HCC with high accuracy. Circulating CSCs may be the target of eradication in the prevention of metastasis of HCC after hepatectomy.
 
DescriptionScientific Session III
 
DC FieldValue
dc.contributor.authorFan, ST
 
dc.contributor.authorYang, ZF
 
dc.contributor.authorHo, DWY
 
dc.contributor.authorYu, WC
 
dc.contributor.authorWong, J
 
dc.date.accessioned2011-06-09T03:47:11Z
 
dc.date.available2011-06-09T03:47:11Z
 
dc.date.issued2011
 
dc.description.abstractOBJECTIVE(S): Recurrence of HCC frequently occurs within the first year after hepatectomy probably due to circulating cancer cells that shed from the primary tumor prior to hepatectomy. Since cancer stem cells (CSCs) are more likely to initiate tumor growth than mature cancer cells, a high level of circulating CSCs may be a hint for HCC recurrence. This study aims to investigate whether circulating CSCs can predict recurrence of HCC after hepatectomy. METHODS: Multi-color flow cytometry was used to detect the number of circulating CSCs (CD45-CD90+CD44+) in the peripheral circulation of 82 patients of HCC one day before hepatectomy. The patients were monitored by CT or MRI for recurrence every three months. RESULTS: Forty-one (50%) patients had recurrence after a median follow-up period of 17.5 months (range 2.7–64.9 months). The patients with recurrence had a higher median level of circulating CSCs than those without recurrence (0.02% vs. 0.01%, p < 0.0001). Circulating CSCs >/=0.01% predicted intrahepatic recurrences (relative risk 3.54, 95% C.I. 1.41–8.88) and extrahepatic recurrences (relative risk 10.15, 95% C.I. 3–34.4). Patients with >0.01% circulating CSCs had a lower two-year disease-free rate (22.7% vs. 64.2%, p < 0.0001) and overall survival rate (58.5% vs. 94.1%, p = 0.0005) than those with </=0.01% circulating CSCs. On multivariate analysis, circulating CSCs >0.01%, tumor stage and tumor size were independent factors affecting the disease-free survival. CONCLUSIONS: Circulating CSCs predicted post-hepatectomy recurrence of HCC with high accuracy. Circulating CSCs may be the target of eradication in the prevention of metastasis of HCC after hepatectomy.
 
dc.descriptionScientific Session III
 
dc.description.otherThe 131st Annual Meeting of the American Surgical Association, Boca Raton, FL., 14-16 April 2011.
 
dc.identifier.citationThe 131st Annual Meeting of the American Surgical Association, Boca Raton, FL., 14-16 April 2011. [How to Cite?]
 
dc.identifier.urihttp://hdl.handle.net/10722/133928
 
dc.languageeng
 
dc.relation.ispartofAnnual Meeting of the American Surgical Association
 
dc.titlePrediction of post-hepatectomy HCC recurrence by circulating cancer stem cells
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Fan, ST</contributor.author>
<contributor.author>Yang, ZF</contributor.author>
<contributor.author>Ho, DWY</contributor.author>
<contributor.author>Yu, WC</contributor.author>
<contributor.author>Wong, J</contributor.author>
<date.accessioned>2011-06-09T03:47:11Z</date.accessioned>
<date.available>2011-06-09T03:47:11Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>The 131st Annual Meeting of the American Surgical Association, Boca Raton, FL., 14-16 April 2011.</identifier.citation>
<identifier.uri>http://hdl.handle.net/10722/133928</identifier.uri>
<description>Scientific Session III</description>
<description.abstract>OBJECTIVE(S): Recurrence of HCC frequently occurs within the first year after hepatectomy probably due to circulating cancer cells that shed from the primary tumor prior to hepatectomy. Since cancer stem cells (CSCs) are more likely to initiate tumor growth than mature cancer cells, a high level of circulating CSCs may be a hint for HCC recurrence. This study aims to investigate whether circulating CSCs can predict recurrence of HCC after hepatectomy. METHODS: Multi-color flow cytometry was used to detect the number of circulating CSCs (CD45-CD90+CD44+) in the peripheral circulation of 82 patients of HCC one day before hepatectomy. The patients were monitored by CT or MRI for recurrence every three months. RESULTS: Forty-one (50%) patients had recurrence after a median follow-up period of 17.5 months (range 2.7&#8211;64.9 months). The patients with recurrence had a higher median level of circulating CSCs than those without recurrence (0.02% vs. 0.01%, p &lt; 0.0001). Circulating CSCs &gt;/=0.01% predicted intrahepatic recurrences (relative risk 3.54, 95% C.I. 1.41&#8211;8.88) and extrahepatic recurrences (relative risk 10.15, 95% C.I. 3&#8211;34.4). Patients with &gt;0.01% circulating CSCs had a lower two-year disease-free rate (22.7% vs. 64.2%, p &lt; 0.0001) and overall survival rate (58.5% vs. 94.1%, p = 0.0005) than those with &lt;/=0.01% circulating CSCs. On multivariate analysis, circulating CSCs &gt;0.01%, tumor stage and tumor size were independent factors affecting the disease-free survival. CONCLUSIONS: Circulating CSCs predicted post-hepatectomy recurrence of HCC with high accuracy. Circulating CSCs may be the target of eradication in the prevention of metastasis of HCC after hepatectomy.</description.abstract>
<language>eng</language>
<relation.ispartof>Annual Meeting of the American Surgical Association</relation.ispartof>
<title>Prediction of post-hepatectomy HCC recurrence by circulating cancer stem cells</title>
<type>Conference_Paper</type>
<description.other>The 131st Annual Meeting of the American Surgical Association, Boca Raton, FL., 14-16 April 2011.</description.other>
</item>